StockNews.AI
RCKT
StockNews.AI
41 days

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

1. Rocket Pharmaceuticals faces a class action lawsuit regarding misleading safety disclosures. 2. The lawsuit involves critical protocol changes in the RP-A501 gene therapy program. 3. A serious adverse event led to a clinical hold and a significant drop in share price. 4. RCKT shares fell nearly 37% after the announcement of a patient death in trials. 5. Investors in the class period may claim recovery; deadline set for August 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The class action lawsuit and share price drop indicate a severe loss of investor confidence. Historical cases, such as those involving Valeant Pharmaceuticals, show that legal actions can lead to prolonged stock declines.

How important is it?

The allegations pertain to investor trust and safety disclosures directly linked to RCKT's primary asset, affecting financial outlook significantly.

Why Short Term?

The immediate effect on RCKT's stock price due to the lawsuit is likely to persist until the litigation is resolved. Short-term investor sentiment could remain bearish as details unfold.

Related Companies

NVDAALNY
, /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company"). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program. Rocket Pharmaceuticals, headquartered in Cranbury, New Jersey, is a biotechnology company focused on developing gene therapies for rare diseases. The suit alleges that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse event (SAE) and subsequent FDA clinical hold. Following the Company's disclosure of a patient death in the trial, RCKT shares fell nearly 37%, from $6.27 on May 23, 2025, to $2.33 on May 27, 2025. Investor Deadline: Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025 (the "Class Period") may be eligible to seek recovery. The deadline to apply for lead plaintiff is August 11, 2025. To learn your rights, CLICK HERE. About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015[email protected] Caitlin AdorniBerger Montague(267) 764-4865[email protected]  SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News